224 related articles for article (PubMed ID: 36697471)
1. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
[TBL] [Abstract][Full Text] [Related]
2. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
4. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
5. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.
Huang CF; Liang PC; Tsai PC; Wei YJ; Huang CI; Wang CW; Jang TY; Yeh ML; Hsu PY; Hsieh MY; Lin YH; Dai CY; Chuang WL; Huang JF; Yu ML
J Gastroenterol Hepatol; 2024 Jan; 39(1):193-201. PubMed ID: 37731071
[TBL] [Abstract][Full Text] [Related]
6. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
7. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
8. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
9. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
Wu X; Li P; Mi YQ
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
[No Abstract] [Full Text] [Related]
11. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study.
Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhao Y; Xu H; Li L; Tong N; Liu F
Acta Diabetol; 2023 Feb; 60(2):225-233. PubMed ID: 36319797
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
Rodriguez-Duque JC; Calleja JL; Iruzubieta P; Hernández-Conde M; Rivas-Rivas C; Vera MI; Garcia MJ; Pascual M; Castro B; García-Blanco A; García-Nieto E; Olmo SC; Cagigal ML; Lopez-Montejo L; Fernández-Lamas T; Rasines L; Fortea JI; Vaque JP; Frias Y; Rivero M; Arias-Loste MT; Crespo J
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):406-414.e7. PubMed ID: 35124272
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
[TBL] [Abstract][Full Text] [Related]
16. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.
Tan YW; Wang JM; Zhou XB
World J Hepatol; 2023 Feb; 15(2):237-254. PubMed ID: 36926239
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
19. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
